Artisan Partners Limited Partnership lowered its position in argenx SE (NASDAQ:ARGX - Free Report) by 12.6% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 3,069,995 shares of the company's stock after selling 443,247 shares during the quarter. argenx makes up about 2.8% of Artisan Partners Limited Partnership's holdings, making the stock its 2nd biggest holding. Artisan Partners Limited Partnership owned about 5.05% of argenx worth $1,888,047,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Whipplewood Advisors LLC purchased a new stake in shares of argenx during the 4th quarter worth $37,000. Global Retirement Partners LLC raised its stake in argenx by 369.2% in the fourth quarter. Global Retirement Partners LLC now owns 61 shares of the company's stock valued at $38,000 after buying an additional 48 shares in the last quarter. Jones Financial Companies Lllp lifted its holdings in argenx by 1,016.7% during the 4th quarter. Jones Financial Companies Lllp now owns 67 shares of the company's stock worth $41,000 after buying an additional 61 shares during the last quarter. Whittier Trust Co. of Nevada Inc. boosted its position in shares of argenx by 78.6% during the 4th quarter. Whittier Trust Co. of Nevada Inc. now owns 75 shares of the company's stock worth $46,000 after acquiring an additional 33 shares in the last quarter. Finally, Farther Finance Advisors LLC increased its holdings in shares of argenx by 38.2% in the 4th quarter. Farther Finance Advisors LLC now owns 76 shares of the company's stock valued at $47,000 after acquiring an additional 21 shares during the last quarter. Institutional investors and hedge funds own 60.32% of the company's stock.
Analyst Ratings Changes
ARGX has been the subject of a number of research analyst reports. Citigroup reaffirmed an "outperform" rating on shares of argenx in a report on Friday, February 28th. HC Wainwright increased their target price on shares of argenx from $717.00 to $720.00 and gave the company a "buy" rating in a research report on Friday, February 28th. Wells Fargo & Company boosted their price target on shares of argenx from $723.00 to $741.00 and gave the company an "overweight" rating in a research report on Friday, February 28th. Oppenheimer raised their price objective on argenx from $675.00 to $704.00 and gave the stock an "outperform" rating in a report on Friday, February 28th. Finally, JMP Securities boosted their target price on argenx from $606.00 to $696.00 and gave the company a "market outperform" rating in a report on Tuesday, January 14th. Three investment analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, argenx currently has a consensus rating of "Moderate Buy" and a consensus price target of $687.00.
Read Our Latest Research Report on ARGX
argenx Trading Down 1.1 %
Shares of NASDAQ:ARGX traded down $6.38 during midday trading on Monday, hitting $582.77. The stock had a trading volume of 178,632 shares, compared to its average volume of 289,357. The company has a market capitalization of $35.41 billion, a PE ratio of -663.44 and a beta of 0.59. argenx SE has a 1 year low of $352.77 and a 1 year high of $678.21. The stock has a 50 day moving average price of $628.26 and a two-hundred day moving average price of $602.12.
argenx (NASDAQ:ARGX - Get Free Report) last released its earnings results on Thursday, February 27th. The company reported $1.58 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.98 by $0.60. The company had revenue of $761.22 million for the quarter, compared to analysts' expectations of $678.52 million. argenx had a negative return on equity of 1.45% and a negative net margin of 2.11%. As a group, equities analysts expect that argenx SE will post 3.13 EPS for the current year.
argenx Profile
(
Free Report)
argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.
Further Reading
Before you consider argenx, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and argenx wasn't on the list.
While argenx currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
